Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875954 | 1.00 | NOTUM (0.46) | NOTUMLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL2875175 | 1.00 | NOTUM (0.46) | NOTUMLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL2878783 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL316646 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL2880648 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL28026037 | 0.86 | NOTUM (0.46) | NOTUMLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL587681 | 0.85 | LMNA (0.53) | LMNAL3MBTL1MAPTRAB9APOLB | |
| Bromide SCHEMBL3964464 | 0.85 | ALDH1A1 (0.47) | MAPTALDH1A1 | |
| SCHEMBL7357706 | 0.85 | ALDH1A1 (0.48) | LMNAPOLBALDH1A1 | |
| SCHEMBL25317162 | 0.82 | LMNA (0.39) | LMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | claimed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | claimed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12465590-B2 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2025-11-11 | — | — | US | disclosed |
| WO-2025215536-A1 | MACROCYCLIC PANRAS INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4532497-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-04-09 | — | — | EP | disclosed |
| CN-116113635-B | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119301132-A | Halogenated indole macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240398963-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118955409-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2003024899-A2 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002055491-A2 | 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) | BRISTOL MYERS SQUIBB COMPANY P (US) | 2002-07-18 | — | — | WO | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1087937-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-1999065867-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | NOTUM 1412/4885LMNA 2122/4885L3MBTL1 4429/4885 |
| US-12465590-B2 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus | OAT, SLC10A1, OTC | NOTUM 1191/4885LMNA 3969/4885L3MBTL1 4179/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | NOTUM 3313/4885LMNA 3574/4885L3MBTL1 3559/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | NOTUM 2681/4885LMNA 90/4885L3MBTL1 2402/4885 |
| US-20240398963-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, KDR, TEK | NOTUM 4822/4885LMNA 2799/4885L3MBTL1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.